Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
REPH Stock Summary
In the News
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.
Recro Reports Inducement Grants For New Staff
Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth
REPH Financial details
REPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.78 | 4.2 | 2.8 | 1.47 | 1.56 | |
Net income per share | -3.9 | -0.79 | -1.16 | -0.52 | -0.34 | |
Operating cash flow per share | -2.11 | -1.08 | 0.34 | 0.21 | -0.06 | |
Free cash flow per share | -2.63 | -1.43 | 0.02 | 0.11 | -0.21 | |
Cash per share | 1.88 | 0.81 | 1 | 0.49 | 0.26 | |
Book value per share | -0.95 | -0.28 | -0.59 | 0.82 | 1.03 | |
Tangible book value per share | -2.84 | -0.61 | -0.81 | -0.06 | 0.27 | |
Share holders equity per share | -0.95 | -0.28 | -0.59 | 0.82 | 1.03 | |
Interest debt per share | 3.57 | 5.52 | 5.42 | 2.31 | -0.01 | |
Market cap | 145.3M | 432.75M | 67.67M | 87.92M | 120.96M | |
Enterprise value | 171.03M | 524.44M | 153.48M | 166.23M | 119.21M | |
P/E ratio | -1.82 | -23.23 | -2.46 | -3.32 | -6.08 | |
Price to sales ratio | 1.88 | 4.36 | 1.02 | 1.17 | 1.34 | |
POCF ratio | -3.37 | -16.97 | 8.39 | 8.1 | -33.2 | |
PFCF ratio | -2.7 | -12.79 | 145.84 | 15.79 | -10.08 | |
P/B Ratio | -7.45 | -64.47 | -4.8 | 2.09 | 2.02 | |
PTB ratio | -7.45 | -64.47 | -4.8 | 2.09 | 2.02 | |
EV to sales | 2.21 | 5.29 | 2.31 | 2.21 | 1.32 | |
Enterprise value over EBITDA | -3.74 | 54.77 | 748.69 | 14.67 | 427.28 | |
EV to operating cash flow | -3.97 | -20.57 | 19.03 | 15.31 | -32.71 | |
EV to free cash flow | -3.18 | -15.5 | 330.78 | 29.85 | -9.94 | |
Earnings yield | -0.55 | -0.04 | -0.41 | -0.3 | -0.16 | |
Free cash flow yield | -0.37 | -0.08 | 0.01 | 0.06 | -0.1 | |
Debt to equity | -3.29 | -16.46 | -7.77 | 2.46 | 0.22 | |
Debt to assets | 0.41 | 1 | 1.06 | 0.65 | 0.08 | |
Net debt to EBITDA | -0.56 | 9.57 | 418.59 | 6.91 | -6.29 | |
Current ratio | 2.45 | 9.28 | 6.93 | 3.24 | 2.44 | |
Interest coverage | -6.17 | 1.19 | -0.44 | 0.25 | 2.34 | |
Income quality | 0.54 | 1.37 | -0.29 | -0.95 | 0.18 | |
Dividend Yield | 0 | 0 | 0 | 0.37 | 0 | |
Payout ratio | 0 | 0 | 0 | -1.21 | 0 | |
Sales general and administrative to revenue | 0.48 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.52 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.25 | 0.07 | 0.05 | 0.28 | 0.28 | |
Capex to operating cash flow | 0.25 | 0.33 | -0.94 | -0.49 | 2.29 | |
Capex to revenue | -0.14 | -0.08 | -0.11 | -0.07 | -0.09 | |
Capex to depreciation | -1.35 | -0.99 | -0.89 | -0.7 | -1 | |
Stock based compensation to revenue | 0.09 | 0.06 | 0.15 | 0.09 | 0.06 | |
Graham number | 9.14 | 2.25 | 3.93 | 3.08 | 2.83 | |
ROIC | -1.55 | 0.19 | -0.09 | 0.06 | -0.44 | |
Return on tangible assets | -0.68 | -0.18 | -0.28 | -0.23 | -0.18 | |
Graham Net | -5.75 | -3.09 | -3.19 | -1.42 | -1.13 | |
Working capital | 42.11M | 53.68M | 46.27M | 39.79M | 32.78M | |
Tangible asset value | -58.21M | -14.31M | -19.12M | -2.85M | 15.85M | |
Net current asset value | -103.85M | -57.01M | -63.45M | -60.72M | -42M | |
Invested capital | -3.29 | -16.46 | -7.77 | 2.46 | 0.22 | |
Average receivables | 13.88M | 20.65M | 19.8M | 18.42M | 18.21M | |
Average payables | 6.23M | 2.75M | 1.4M | 1.94M | 1.78M | |
Average inventory | 10.27M | 12.89M | 13.34M | 10.26M | 9.61M | |
Days sales outstanding | 85.26 | 85.49 | 89.81 | 99.18 | 64.53 | |
Days payables outstanding | 38.14 | 7.08 | 12.16 | 13.7 | 7.98 | |
Days of inventory on hand | 90.48 | 107.91 | 78.29 | 58.6 | 56.05 | |
Receivables turnover | 4.28 | 4.27 | 4.06 | 3.68 | 5.66 | |
Payables turnover | 9.57 | 51.55 | 30.01 | 26.64 | 45.75 | |
Inventory turnover | 4.03 | 3.38 | 4.66 | 6.23 | 6.51 | |
ROE | 4.09 | 2.78 | 1.95 | -0.63 | -0.33 | |
Capex per share | -0.52 | -0.35 | -0.32 | -0.1 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.38 | 0.42 | 0 | 0 | 0 | |
Net income per share | -0.12 | -0.16 | 0 | 0 | 0 | |
Operating cash flow per share | 0.01 | 0.03 | 0 | 0 | 0 | |
Free cash flow per share | -0.03 | -0.01 | 0 | 0 | 0 | |
Cash per share | 0.2 | 0.26 | 0 | 0 | 0 | |
Book value per share | 0.62 | 1.03 | 0 | 0 | 0 | |
Tangible book value per share | -0.16 | 0.27 | 0 | 0 | 0 | |
Share holders equity per share | 0.62 | 1.03 | 0 | 0 | 0 | |
Interest debt per share | 0.2 | -0.19 | 0 | 0 | 0 | |
Market cap | 118.43M | 120.96M | 177.23B | 182.52B | 210.33B | |
Enterprise value | 114.65M | 119.21M | 177.24B | 0 | 210.34B | |
P/E ratio | -4.31 | -3.3 | -9.46K | -14.21K | -11.45K | |
Price to sales ratio | 5.49 | 4.98 | 8.23K | 8.37K | 8.92K | |
POCF ratio | 250.39 | 60.66 | -62.12K | 0 | 0 | |
PFCF ratio | -64.51 | -163.03 | -28.45K | 0 | 0 | |
P/B Ratio | 3.36 | 2.02 | 3.17K | 0 | 3.61K | |
PTB ratio | 3.36 | 2.02 | 3.17K | 0 | 3.61K | |
EV to sales | 5.31 | 4.91 | 8.23K | 0 | 8.92K | |
Enterprise value over EBITDA | 48.15 | -3.08 | -68.22K | 0 | -119.71K | |
EV to operating cash flow | 242.38 | 59.78 | -62.12K | 0 | 0 | |
EV to free cash flow | -62.44 | -160.66 | -28.45K | 0 | 0 | |
Earnings yield | -0.06 | -0.08 | 0 | 0 | 0 | |
Free cash flow yield | -0.02 | -0.01 | 0 | 0 | 0 | |
Debt to equity | 0.22 | 0.22 | 0.24 | 0 | 0.26 | |
Debt to assets | 0.05 | 0.08 | 0.09 | 0 | 0.1 | |
Net debt to EBITDA | -1.59 | 0.05 | -2.74 | 0 | -4.04 | |
Current ratio | 3.49 | 2.44 | 2.45 | 0 | 2.3 | |
Interest coverage | 0.06 | 1.33 | 3.15 | 0.42 | 0.6 | |
Income quality | -0.14 | -0.22 | 0.61 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.29 | 0.28 | 0.29 | 0 | 0.29 | |
Capex to operating cash flow | -4.88 | -1.37 | 1.18 | 0 | 0 | |
Capex to revenue | -0.11 | -0.11 | -0.16 | 0 | 0 | |
Capex to depreciation | -1.07 | -1.29 | -1.62 | 0 | 0 | |
Stock based compensation to revenue | 0.06 | 0.05 | 0.05 | 0 | 0 | |
Graham number | 1.3 | 1.92 | 0 | 0 | 0 | |
ROIC | 0.01 | -0.47 | -0.09 | 0 | -0.02 | |
Return on tangible assets | -0.06 | -0.08 | -0.04 | 0 | -0.04 | |
Graham Net | -1.53 | -1.13 | 0 | 0 | 0 | |
Working capital | 35.31M | 32.78M | 28.31M | 0 | 28.16M | |
Tangible asset value | -8.99M | 15.85M | 12.16M | 0 | 14.77M | |
Net current asset value | -66.55M | -42M | -46.12M | 0 | -43.49M | |
Invested capital | 0.22 | 0.22 | 0.24 | 0 | 0.26 | |
Average receivables | 16.81M | 16.53M | 15.59M | 0 | 0 | |
Average payables | 2.7M | 2.26M | 1.93M | 0 | 0 | |
Average inventory | 8.89M | 9.86M | 10.94M | 0 | 0 | |
Days sales outstanding | 71.3 | 59.13 | 63.67 | 0 | 56.35 | |
Days payables outstanding | 17.14 | 7.57 | 11.17 | 0 | 9.62 | |
Days of inventory on hand | 52.77 | 53.17 | 54.03 | 0 | 55.62 | |
Receivables turnover | 1.26 | 1.52 | 1.41 | 0 | 1.6 | |
Payables turnover | 5.25 | 11.89 | 8.06 | 0 | 9.35 | |
Inventory turnover | 1.71 | 1.69 | 1.67 | 0 | 1.62 | |
ROE | -0.2 | -0.15 | -0.08 | 0 | -0.08 | |
Capex per share | -0.04 | -0.05 | 0 | 0 | 0 |
REPH Frequently Asked Questions
What is Recro Pharma, Inc. stock symbol ?
Recro Pharma, Inc. is a US stock , located in Malvern of Pennsylvania and trading under the symbol REPH
What is Recro Pharma, Inc. stock quote today ?
Recro Pharma, Inc. stock price is $- today.
Is Recro Pharma, Inc. stock public?
Yes, Recro Pharma, Inc. is a publicly traded company.